Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial-Reference-Cited by-同舟云学术

Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial

Published:2012-05-01 Issue:3 Volume:15 Page:303-307
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Kellokumpu-Lehtinen P-L, ,Hjälm-Eriksson M,Thellenberg-Karlsson C,Åström L,Franzen L,Marttila T,Seke M,Taalikka M,Ginman C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/pcan201213.pdf

Reference34 articles.

1. Stattin P, Holmberg E, Johansson J-E, Holmberg L, Adolfsson J, Hogosson J . Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950–958.

2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. Natl Cancer Inst 1998; 90: 766–771.

3. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002; 20: 3206–3612.

4. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57: 1033–1037.

5. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial;BMC Cancer;2022-02-16

2. Combined Therapy for the Treatment of Cancer;Chemotherapy Protocols and Infusion Sequence;2022

3. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis;Cancer Cell;2021-01

4. Nano Ellagic Acid Counteracts Cisplatin-Induced Upregulation in OAT1 and OAT3: A Possible Nephroprotection Mechanism;Molecules;2020-07-02

5. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial;European Urology;2019-12